Abstract |
To evaluate the efficacy of adjuvant immunochemotherapy, especially the long-term administration of HCFU to patients with noncuratively resected and unresected gastric cancer, a randomized controlled study was conducted by 16 institutions in Hokkaido. After surgery, 185 patients were divided into two groups using the envelope method; group A (84 patients) treated by MMC (4 mg, twice a week, total 1 mg/kg)+ OK-432 (or PSK): group B (101 patients) treated with MMC+OK-432+HCFU (600 mg, per day). The 5- and 10-year survival rates were 9.8 and 3.1% in group A, and 11.1 and 11.1% in group B (p=0.062). Better survival rates were obtained in those cases with unresected, S3, or peritoneal dissemination in group B. These results suggested the long-term administration of HCFU was effective for noncuratively resected and unresected gastric cancer.
|
Authors | S Osawa, H Shiroto, Y Kondo, Y Nakanishi, J Fujisawa, K Miyakawa, T Oku, A Nishimura, J Uchino |
Journal | Gan to kagaku ryoho. Cancer & chemotherapy
(Gan To Kagaku Ryoho)
Vol. 23
Issue 3
Pg. 327-31
(Feb 1996)
ISSN: 0385-0684 [Print] Japan |
PMID | 8712826
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Picibanil
- Mitomycin
- carmofur
- Fluorouracil
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Chemotherapy, Adjuvant
- Chi-Square Distribution
- Combined Modality Therapy
- Fluorouracil
(administration & dosage, analogs & derivatives)
- Follow-Up Studies
- Humans
- Immunotherapy
- Japan
- Mitomycin
(administration & dosage)
- Picibanil
(administration & dosage)
- Stomach Neoplasms
(drug therapy, surgery, therapy)
|